Adriamycin-induced heart failure: mechanisms and modulation
作者： Pawan Singal , Timao Li , Dinender Kumar , Igor Danelisen , Natasha Iliskovic
关键词:
摘要: Adriamycin (doxorubicin) is one of the most effective chemotherapeutic agents against a variety cancers, but its usefulness seriously curtailed by risk developing heart failure. Available laboratory evidence suggests that an increase in oxidative stress, brought about increased free radical production and decreased myocardial endogenous antioxidants, plays important role pathogenesis Adriamycin-induced apoptosis hyperlipidemia may also be involved process. Probucol, lipid-lowering drug antioxidant, completely prevents occurrence failure reducing stress as well modulation apoptis high lipid concentrations. Thus, combined therapy with adriamycin probucol has potential for optimizing treatment cancer patients.
springer.com
sci-hub.se 参考文章(101)
Stephen Epstein, Charles Myers, Charles Myers, Charles Myers, Brian Corden, Brian Corden, Brian Corden, Sebastian Palmeri, Sebastian Palmeri, Sebastian Palmeri, James Doroshow, James Doroshow, James Doroshow, Robert Bonow, Gershon Locker, Gershon Locker, Gershon Locker, Jean Jenkins, Jean Jenkins, Jean Jenkins, Stephen Epstein, Stephen Epstein, A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Seminars in Oncology. ,vol. 10, pp. 53- 55 ,(1983)
M Gaetani, A Di Marco, B Scarpinato, Adriamycin (NSC-123,127): a new antibiotic with antitumor activity. Cancer chemotherapy reports. ,vol. 53, pp. 33- ,(1969)
Reginald L. Reagan, David J. Prieur, Harry M. Olson, David M. Young, Andre F. LeRoy, Electrolyte and morphologic alterations of myocardium in adriamycin-treated rabbits. American Journal of Pathology. ,vol. 77, pp. 439- 454 ,(1974)
P. K. Singal, N. Iliskovic, Lipid lowering: an important factor in preventing adriamycin-induced heart failure. American Journal of Pathology. ,vol. 150, pp. 727- 734 ,(1997)
Singal Pk, Hill M, Kaul N, Khaper N, Thomas Tp, Siveski-Iliskovic N, Probucol improves antioxidant activity and modulates development of diabetic cardiomyopathy. Nutrition. ,vol. 11, pp. 551- ,(1995)
Singal Pk, Kirshenbaum La, A relative deficit in antioxidant reserve may contribute in cardiac failure. Canadian Journal of Cardiology. ,vol. 6, pp. 47- 49 ,(1990)
F. Arcamone, G. Cassinelli, G. Franceschi, S. Penco, C. Pol, S. Redaelli, A. Selva, Structure and Physicochemical Properties of Adriamycin (Doxorubicin) Springer, Berlin, Heidelberg. pp. 9- 22 ,(1972) , 10.1007/978-3-642-95227-2_2
P K Singal, M J Kutryk, R J Segstro, R P Singh, Changes in lysosomal morphology and enzyme activities during the development of adriamycin-induced cardiomyopathy. Canadian Journal of Cardiology. ,vol. 1, pp. 139- 147 ,(1985)
Stephen H. Rosenoff, Harry M. Olson, David M. Young, Frieda Bostick, Robert C. Young, Brief Communication: Adriamycin-Induced Cardiac Damage in the Mouse: A Small-Animal Model of Cardiotoxicity Journal of the National Cancer Institute. ,vol. 55, pp. 191- 194 ,(1975) , 10.1093/JNCI/55.1.191
J P Reeves, L M Buja, R A Prough, J T Willerson, K H Muntz, D Kruk, J A Jackson, Evaluation of free radical effects and catecholamine alterations in adriamycin cardiotoxicity. American Journal of Pathology. ,vol. 117, pp. 140- 153 ,(1984)